Apply now: feature your voice in our cell & gene therapy series
Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community?
We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice!
A recent study by García et al. (2025) has found that urolithin A (UroA), a compound produced by gut bacteria, could be a promising addition to multiple myeloma treatment. UroA is generated when we eat foods like berries and nuts, and its presence in the gut has been linked to better outcomes for patients with this cancer. The study showed that UroA can kill cancer cells by disrupting their energy production and preventing them from multiplying. This effect was confirmed in both cell cultures and mouse models, where UroA-treated mice lived longer.
In addition to its direct effects on cancer cells, UroA was found to enhance the effectiveness of a common multiple myeloma drug, even in drug-resistant cells. These findings suggest that UroA has the potential to not only slow down the progression of multiple myeloma but also to improve the response to existing therapies, offering a beacon of hope for developing a cure for this currently incurable disease.
More Info 
Add to Calendar 